What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The FDA has been cracking down on compounded versions of GLP-1 agonists like semaglutide and tirzepatide. Here's a breakdown of what's happening and who is still operating legally:

What happened with the FDA and compounded GLP-1s?

The FDA's primary concern is with compounded versions of GLP-1s that are identical to the brand-name drugs (e.g., compounded semaglutide that is chemically identical to Ozempic or Wegovy). The FDA has stated that these types of compounded drugs:

• Do not meet the criteria for compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. These sections allow for compounding under specific circumstances, primarily when a physician determines a commercially available drug is not suitable for a patient and the compounded drug is based on an "evaporated" drug (meaning the original drug is no longer commercially available, or there are specific shortages).
• May not be safe or effective. The FDA has raised concerns about the quality, purity, and potency of some compounded versions, especially when they are not prepared by FDA-registered outsourcing facilities.
• Undermine the FDA's regulatory oversight. The FDA's approval process ensures the safety and efficacy of drugs through rigorous clinical trials. Compounded versions that are chemically identical bypass this oversight.
• Can be marketed in a way that is misleading. Some compounding pharmacies have been accused of marketing these compounded drugs as direct alternatives to the brand-name medications, which can be confusing for consumers.

In essence, the FDA is stating that if a brand-name drug is commercially available, compounding a chemically identical version is generally not permissible under current regulations.

Who is still operating legally?

This is where it gets nuanced. The FDA's actions have primarily targeted compounding pharmacies that are creating chemically identical versions of the brand-name GLP-1s.

Here's what is generally considered to be operating legally, or at least outside the direct scope of the FDA's current enforcement actions against identical copies:

1. Brand-Name Medications from Approved Manufacturers: The most straightforward and legally sound way to access GLP-1s is through prescription of the FDA-approved brand-name medications:

   • Ozempic® (semaglutide) and Wegovy® (semaglutide) by Novo Nordisk: For type 2 diabetes and weight management, respectively.
   • Rybelsus® (semaglutide) by Novo Nordisk: An oral form for type 2 diabetes.
   • Mounjaro® (tirzepatide) and Zepbound® (tirzepatide) by Eli Lilly: For type 2 diabetes and weight management, respectively.

   These medications have undergone extensive FDA review and are manufactured under strict quality controls.

2. Compounded Drugs Based on DIFFERENT Active Pharmaceutical Ingredients (APIs): Some compounding pharmacies are creating "compounded" weight loss or diabetes medications that use different APIs or combinations of APIs than the brand-name GLP-1s. These might include:

   • Sermorelin: A growth hormone-releasing hormone analog.
   • CJC-1295/Ipamorelin: Peptides that stimulate growth hormone release.
   • B vitamins, amino acids, and other metabolic support agents.

   These compounded products are not chemically identical to semaglutide or tirzepatide, and therefore do not fall under the FDA's direct enforcement actions against identical copies. However, their efficacy for weight loss or diabetes management is often based on less robust scientific evidence compared to the approved GLP-1s, and their legality can still be debated depending on the specific ingredients and claims made.

Important Considerations for Consumers:

• Be Wary of "Compounded Semaglutide" or "Compounded Tirzepatide": If a compounding pharmacy is offering a product that is explicitly marketed as "compounded semaglutide" or "compounded tirzepatide" and is intended to be chemically identical to Ozempic/Wegovy or Mounjaro/Zepbound, it is likely operating in a gray area and may face future FDA scrutiny.
• Consult Your Doctor: Always discuss any treatment options, including compounded medications, with your healthcare provider. They can help you understand the risks, benefits, and legal standing of different options.
• Verify Pharmacy Credentials: If considering a compounded medication (even one with different APIs), ensure the compounding pharmacy is reputable and, if applicable, an FDA-registered outsourcing facility.
• Understand the Evidence: Be critical of claims made about compounded drugs. The FDA-approved GLP-1s have extensive clinical trial data supporting their efficacy and safety. The evidence for many other compounded formulations is less substantial.

In summary, the FDA's current focus is on preventing the compounding of chemically identical copies of existing, commercially available GLP-1s. Legally operating entities are either providing the approved brand-name drugs or, in the case of compounding pharmacies, offering formulations with different active ingredients.